Switching from Lexapro 20 mg to Luvox
When switching from escitalopram (Lexapro) 20 mg to fluvoxamine (Luvox), perform a gradual taper of escitalopram over 10-14 days, then start fluvoxamine at 50 mg daily after the taper is complete, avoiding any washout period since both are SSRIs without MAOI risk.
Rationale for the Switch Strategy
The evidence supports a conservative cross-taper approach when switching between SSRIs, though the specific method depends on pharmacokinetic properties of each medication 1, 2.
Key Pharmacokinetic Considerations
Escitalopram characteristics:
- Has minimal effect on CYP450 enzymes compared to other SSRIs, resulting in lower drug interaction potential 2
- Shorter half-life requiring dose adjustments at 1-2 week intervals 2
- Associated with discontinuation syndrome if stopped abruptly 2
Fluvoxamine characteristics:
- Significant CYP450 interactions (affects CYP1A2, CYP2C19, CYP2C9, CYP3A4, and CYP2D6) 2
- Associated with discontinuation syndrome 2
- Starting dose is 50 mg twice daily per FDA labeling, though 50 mg once daily at bedtime is acceptable initially 3
Specific Switching Protocol
Step 1: Taper Escitalopram
- Reduce escitalopram from 20 mg to 10 mg daily for 7 days
- Then reduce to 5 mg daily for 3-7 days
- Total taper duration: 10-14 days 1
This gradual reduction minimizes discontinuation syndrome symptoms including dizziness, fatigue, nausea, sensory disturbances, anxiety, and irritability 2, 4.
Step 2: Initiate Fluvoxamine
- Start fluvoxamine 50 mg once daily at bedtime immediately after completing the escitalopram taper 3
- No washout period is required since both are SSRIs and MAOI contraindications do not apply 3, 4
- After 4-7 days, increase to 50 mg twice daily if tolerated 3
- Continue titrating by 50 mg increments every 4-7 days as needed, up to maximum 300 mg/day 3
Step 3: Monitor Closely
Critical monitoring period: First 24-48 hours after each dose change 2
Watch for:
- Serotonin syndrome symptoms: confusion, agitation, tremors, hyperreflexia, muscle rigidity, hypertension, tachycardia, diaphoresis 2
- Discontinuation symptoms from escitalopram: dizziness, paresthesias, anxiety, nausea, insomnia 2, 4
- New adverse effects from fluvoxamine: nausea, somnolence, insomnia, nervousness 2
- Behavioral activation: agitation, restlessness, impulsiveness 2
Important Safety Considerations
Drug Interactions
Fluvoxamine has substantially greater drug interaction potential than escitalopram 2. Review all concurrent medications, particularly:
- Benzodiazepines (reduce alprazolam/triazolam dose by 50% if co-administered) 1, 2
- Medications metabolized by multiple CYP450 enzymes 2
- QT-prolonging medications 2
Contraindications
- Absolute: Do not combine with MAOIs - maintain 14-day separation 3, 4
- Caution: Avoid combining with other serotonergic drugs without careful monitoring 2
Special Populations
- Elderly or hepatically impaired: Start fluvoxamine at 25 mg daily and titrate more slowly 3
- Pregnancy (third trimester): Consider risks vs benefits; may need to taper before delivery 3
Common Pitfalls to Avoid
Abrupt discontinuation of escitalopram: Always taper over 10-14 days to prevent withdrawal symptoms 1, 4, 5
Starting fluvoxamine at full dose: Begin at 50 mg daily, not the target therapeutic dose of 100-300 mg 3
Inadequate monitoring for serotonin syndrome: Though risk is low when switching between SSRIs (not combining them), monitor closely in first 48 hours after starting fluvoxamine 2
Ignoring drug interactions: Fluvoxamine requires comprehensive medication review due to extensive CYP450 interactions 2
Premature dose escalation: Wait full 4-7 days between fluvoxamine dose increases to assess tolerability 3
Expected Timeline
- Weeks 1-2: Escitalopram taper with potential mild discontinuation symptoms
- Week 2-3: Fluvoxamine initiation at low dose
- Weeks 3-6: Gradual fluvoxamine titration to therapeutic dose
- Weeks 6-12: Assessment of therapeutic response 2
The entire switching process typically requires 6-12 weeks to achieve optimal dosing and clinical response 2.